EOM Participant Resources

• EOM Cohort 2 Request for Applications (PDF)
• EOM Cohort 2 Fact Sheet
• EOM FAQs
• EOM PGP Fact Sheet (PDF)
• EOM Payer Fact Sheet (PDF)

• EOM Beneficiary Notification Letter (PDF)
• EOM Beneficiary Notification Letter - Spanish (PDF)
• EOM Participants (XLSX)
• EOM Participant Portal
• EOM Participant Portal Access User Manual (PDF)

• EOM Electronic Patient Reported Outcomes Factsheet (PDF)
• EOM Electronic Patient Reported Outcomes Guide v2.4 (PDF)
• EOM Health Related Social Needs Guide v2.4 (PDF)

• EOM Benefit Enhancement Factsheet (PDF)

• EOM Benchmarking Factsheet (PDF)
• EOM Experience Adjuster Factsheet (PDF)
• EOM Payment Methodology v6.0 (PDF)
  • Quality Scoring Update Effective January 1, 2025 (PDF)
  • EOM Payment Methodology Updates Effective January 1, 2025 (PDF)
  • EOM Payment Methodology Updates Effective July 1, 2024 (PDF)
  • EOM Technical Payment Resources (XLSX)

• EOM Initiating Therapies List PP6 v1.0 (XLSX)
• EOM Novel Therapies List v1.26 (November 2025) (XLSX)
• Bispecific Antibody and CAR-T Code List v4 (XLSX)
• EOM Initiating Therapies List PP5 v1.0 (XLSX)
• EOM Initiating Therapies List PP4 v1.2 (XLSX)
• EOM Initiating Therapies List PP3 v1.4 (XLSX)
• EOM Initiating Therapies List PP2 v1.4 (XLSX)
• EOM Initiating Therapies List PP1 v1.5 (XLSX)

• EOM Clinical Data Elements Guide v2.4 (PDF)
• EOM Sociodemographic Data Elements Guide v2.5 (PDF)
• EOM Quality Measures Guide (ZIP)

• EOM DRA Data Dictionary (XLSX)
• Deidentified Public Use Baseline Episode File - CY 2016 (CSV)
• Deidentified Public Use Baseline Episode File - CY 2017 (CSV)
• Deidentified Public Use Baseline Episode File - CY 2018 (CSV)
• Deidentified Public Use Baseline Episode File - CY 2019 (CSV)
• Deidentified Public Use Baseline Episode File - CY 2020 (CSV)
• EOM Data Dictionary for the Deidentified Public Use Baseline Episode Files (XLSX)

• EOM Cost and Quality Performance Data File (Performance Period 1) (XLSX)

Beginning with Performance Period (PP) 6, as part of the updates to the Enhancing Oncology Model (EOM) Third Amended and Restated Participation Agreement (A&R PA) for Cohort 1 participants and the Enhancing Oncology Model (EOM) First Amended and Restated Participation Agreement for Cohort 2 participants, a new Substance Access BEI will give model participants the option of consulting with their patients about the possible use of eligible hemp products. The implementation of this BEI and any related dispensing would be funded entirely at the participant’s expense; CMS would not cover the cost of such products. Further, CMS will have strict program integrity safeguards to ensure that these incentives do not result in program or patient abuse.

The Substance Access BEI is only available to participants in states where the eligible hemp products are considered legal.

The Substance Access BEI is also being made available to participants in the ACO REACH Model starting in performance year 2026 and in the upcoming LEAD Model, which begins on January 1, 2027.

June 2024

• EOM Overview and Application Support Webinar (June 24 from 1:00-2:00 PM ET)
  • Slides (PDF) 

July 2024

• EOM Payment Methodology Webinar (July 18 from 1:00-2:30 PM ET)
  • Slides (PDF) 

August 2024

• Cohort 2 Application Support Office Hour (August 1 from 1:00-2:00 PM ET)
  • Slides (PDF)
• Quality, Health Equity and Clinical Data Strategy Webinar (August 15 from 1-2:30 PM ET)
  • Slides (PDF)
• Cohort 2 Application Support Office Hour #2 (August 29 from 1:00-2:00 PM ET)
  • Slides (PDF)